Quick Answer
Tvardi Therapeutics, Inc. reported Operating Income of -$26.75 million for fiscal year 2025.
Tvardi Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$26.75M | +4.8% |
| 2024 | -$28.11M | +76.9% |
| 2023 | -$121.50M | -38.8% |
| 2022 | -$87.53M | +1.7% |
| 2021 | -$89.08M | -1754.3% |
| 2020 | $5.38M | +104.8% |
| 2019 | -$111.68M | -44.3% |
| 2018 | -$77.38M | -30.1% |
| 2017 | -$59.48M | -1.9% |
| 2016 | -$58.40M | -131.9% |
| 2015 | -$25.19M | -39.4% |
| 2014 | -$18.07M | -7525.3% |
| 2013 | -$237.0K | +96.2% |
| 2012 | -$6.24M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.94M | -4.6% | +33.0% |
| June 30, 2025 | -$8.87M | -23.5% | -271.7% |
| March 31, 2025 | -$2.39M | +92.0% | +58.0% |
| September 30, 2024 | -$5.68M | +80.4% | +21.0% |
| June 30, 2024 | -$7.18M | +77.8% | +75.8% |
| March 31, 2024 | -$29.67M | -7.3% | -2.7% |
| September 30, 2023 | -$28.90M | -21.2% | +10.6% |
| June 30, 2023 | -$32.34M | -623.2% | -17.0% |
- Tvardi Therapeutics, Inc. showed an increase of +4.8% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Tvardi Therapeutics, Inc.’s operating income has declined by 328.9% (from -$6.24 million to -$26.75 million).
- The most recent figure is from Tvardi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: